CASI — CASI Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $26.96m
- $38.93m
- $28.54m
- 39
- 42
- 22
- 25
Annual income statement for CASI Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 20-F | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 15.1 | 30.2 | 43.1 | 33.9 | 28.5 |
| Cost of Revenue | |||||
| Gross Profit | 5.63 | 17.6 | 27.3 | 20.1 | 15.9 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 66.7 | 72.9 | 77.1 | 61 | 68.2 |
| Operating Profit | -51.5 | -42.7 | -34 | -27.1 | -39.6 |
| Total Net Non Operating Interest Income / Expense | |||||
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -47.5 | -35.8 | -37.4 | -26.3 | -38.1 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -47.5 | -35.8 | -39.4 | -26.2 | -38.1 |
| Minority Interest | |||||
| Equity in Affiliates | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -46.6 | -35.1 | -31.5 | -23.7 | -39.3 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -48.3 | -36.7 | -41 | -27 | -39.3 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.72 | -2.15 | -2.49 | -1.92 | -2.23 |